Offering safer alternatives to cigarettes, such as e-cigarettes and heated tobacco products, to smokers who are not willing to quit could reduce the harm caused by smoking. Extensive and rigorous scientific studies are conducted to assess the relative risk of such potentially modified risk tobacco products compared with that of smoking cigarettes. In addition to the peer review of publications reporting individual studies, we aimed to gauge the plausibility of the evidence to the scientific community and appreciate likely necessary additions prior to regulatory submission. Therefore, we sponsored a two-tier peer review organized by an independent third party who identified, recruited, and managed 7 panels of 5-12 experts whose identity remains unknown to us. The reviewers had access to all publications and raw data from preclinical and clinical studies via a web portal. The reviewers were asked questions regarding study design, methods, quality of data, and interpretation of results to judge the validity of the conclusions regarding the relative effects of the Tobacco Heating System 2.2 compared with cigarettes. Once their conclusions were submitted, the experts had the opportunity to participate in an anonymized online debate with their fellow panel members. We present here the results obtained from this innovative peer review effort which revealed supportive or very supportive of the study methods and results, and support the robustness of the studies and validity of the conclusions.
1. Introduction 1.1. Scientific assessment of the Tobacco Heating System 2.2, a candidate modified risk tobacco product, in the context of tobacco harm reduction Smoking cigarettes causes serious diseases, including cardiovascular disease (CVD), lung cancer, and chronic obstructive pulmonary disease (U.S. Department of Health and Human Services, 2010) . However, it has been estimated that more than one billion people worldwide will continue to smoke in the foreseeable future (Eriksen et al., 2015) . In addition to existing strategies for reducing smoking-related harm (i.e., preventing initiation and promoting cessation of smoking), a growing number of health authorities and experts now believe that giving smokers access to less-harmful alternatives can yield significant benefits to public health (Berman et al., 2015; McNeill and Munafo, 2013; The Royal College of Physicians, 2016) . This tobacco harm-reduction approach depends on developing modified-risk tobacco products (MRTP) that meet two conditions: they present less risk than continuing to smoke cigarettes, and they provide a satisfying experience so that smokers make the switch (Smith et al., 2016) .
The U.S. Family Smoking Prevention and Tobacco Control Act defines an MRTP as any tobacco product that is sold or distributed for use to reduce harm or the risk of tobacco-related disease associated with commercially marketed tobacco products (Food and Drug Administration (FDA), 2009). A consistent, science-based framework should be used to identify innovative alternative products that could significantly reduce disease and death caused by cigarette smoking (Hatsukami et al., 2012; Kozlowski and Abrams, 2016; Morven Dialogues, 2015) . We have conducted extensive and rigorous scientific studies following a seven-step MRTP assessment framework ( Fig. 1) (Smith et al., 2016) on our candidate MRTP, the Tobacco Heating System (THS) 2.2, to determine whether we could support claims of reduced exposure to harmful and potentially harmful constituents (HPHC) in smoke, and ultimately claims of reduced disease risk, compared with smoking cigarettes.
The first step of the assessment strategy relates to manufacturing and product performance. The second assessment step is designed to analyze the chemical composition of the aerosol generated by the candidate MRTP (aerosol physics and chemistry) and to quantify the reduction in HPHCs (Schaller et al., 2016) . The third step of the assessment focuses on whether the reduced formation of HPHCs does lead T to reduced toxicity in laboratory models (i) in vitro (in vitro standard toxicity assessment (Schaller et al., 2016) , including neutral red assay, Ames assay, and mouse lymphoma assay), as well as (ii) in vivo (90-day OECD Test Guide 413 study in rats (Wong et al., 2016) ). The fourth step of the assessment determines whether reduced formation of HPHCs and reduced toxicity in laboratory models also lead to reduced risk in laboratory models (i) in vitro (CVD in vitro mechanistic assays: transendothelial migration assay (van der Toorn et al., 2015) and monocyte adhesion assay (Poussin et al., 2016) and systems toxicology assessment of THS 2.2 in nasal and bronchial epithelial tissue cultures exposed to whole reference cigarette smoke or whole THS aerosol at the air-liquid interface (Iskandar et al., 2017; Zanetti et al., 2017) ) and (ii) in vivo (eight-month systems toxicology inhalation/cessation study in Apoe −/ − mice (Lo Sasso et al., 2016; Phillips et al., 2016; Szostak et al., 2017; Titz et al., 2016) ). The primary objective of this pivotal in vivo study was to evaluate whether the use of THS had the potential to reduce the risk of CVD. The secondary objective was to evaluate whether switching from cigarette smoke exposure to THS aerosol exposure led to positive changes that approached those caused by smoking cessation in this mouse model. Finally, as part of the fifth step of the assessment, clinical studies are used to assess whether the reduced formation of HPHCs leads to reduced exposure and risk in humans who use the candidate MRTP. Finally, the sixth and seven steps address consumer perception and behavior and, once the product is on the market, post-market surveillance.
Peer review
It is critical that the evidence supporting exposure or risk reduction potential for a candidate MRTP is reviewed by experts. The role of peer review includes quality control of scientific publications, which serve as the foundation of furthering research, granting funding to researchers, and, very importantly, regulating consumer products. Regulatory agencies, for instance, rely on peer review to ensure that the quality and scientific integrity of their assessments and decisions are maintained (EPA (United States Environmental Protection Agency), 2015; Office of Management and Budget, 2004; The National Academies, 2003; U.S. Environmental Protection Agency Office Of Inspector General, 2009; U.S. Food and Drug Administration, 2012) .
The Committee on Publication Ethics brings together key stakeholders to summarize roles and responsibilities and provide guidelines for authors, editors, and peer reviewers (https://publicationethics.org/ ). However, there is no overarching modus operandi for the peer review process (Table 1) , and not all peer reviews have the same objectives, cover the same depth, or, as a result, inspire the same level of confidence ( Fig. 2A ).
Scope and depth of peer review
The scope and depth of a peer review can vary widely between peer review systems. While journal peer reviews are generally conducted in an unstructured manner, with perhaps a few categorical questions rating the overall importance and originality of the manuscript, peer reviews conducted on dossiers submitted for regulatory agency decisions and assessment typically include a specific set of questions that guide the scope of the panel review (World Health Organization (WHO), 2014; World Health Organization (WHO), 2015) .
Many companies and agencies perform peer reviews as part of product risk assessment. For example, risk-ranking methods are available to prioritize food safety risks (van Asselt et al., 2012 S. Boué, et al. Regulatory Toxicology and Pharmacology 104 (2019) 115-127 Table 1 Comparison of peer review models.
Journal editorial reviews
Regulatory agency reviews Industry-sponsored review reported here
Panel composition
Number of reviewers 1-3 (Cho and Park, 2013) ≥10 5-12 members per panel
Selection criteria
Often not transparent; potential bias cannot be judged (Ho et al., 2013; Manchikanti et al., 2015) Predefined criteria for expertise and assessment by independent auditors
Competency of reviewers
• Depends on journal and availability of reviewers • Lack of expertise may lead to an inability to detect significant flaws during peer review (Manchikanti et al., 2015) • Usually disclosed identity; possible social/peer pressure (Batra, 2015; Rost, 2015) Reviewers remained anonymous, but expertise criteria were disclosed
Peer review process Time allocated by the reviewers for the review 2-5 h (median, highly variable) throughout 2-4 weeks (Cho and Park, 2013) More extended engagement (months to years) 3-8 days' work throughout 1-2 months Compensation Typically no monetary compensation; occasional nonmonetary incentives (e.g., limited electronic access to publisher holdings, continuing education credits, acknowledgments, appointments to review boards) (Gasparyan et al., 2013) Monetary compensation (honoraria and travel costs)
Monetary compensation (time)
Interaction with other reviewers None Encouraged (face-to-face deliberations, conference calls, emails exchange); risk of groupthink (Sunstein and Hastie, 2014) majority of methods are based on the "technical" concept of risk being a function of the presence of the hazard and the severity of its impact on human health (National Research Council -Division on Earth and Life Studies -Board on Environmental Studies and Toxicology -Committee on Improving Risk Analysis Approaches Used by the U.S. EPA, 2009).
Review panel composition and balance
While multiple factors should be considered when establishing review panels, the expertise and independence in panel composition are of principal importance (Meek et al., 2007) ; it is as crucial as it is delicate to precisely define and assess the required expertise. Factors such as technical expertise can be established by objective metrics (e.g., publication record, h-index, years of experience), but they are rarely the only factors considered.
To support risk assessment, manufacturers of chemicals (or other potentially risky products) may sponsor a review of their assessment results. For example, the nonprofit organization Toxicology Excellence for Risk Assessment (TERA, https://www.tera.org) provides peer consultation and peer review services and convenes groups of experts to evaluate the scientific basis of the work products and its conclusions following U.S. Environmental Protection Agency (EPA) peer review procedures.
Peer reviews conducted for regulatory decisions and assessments usually include larger panels than are typical of scientific publication peer review (Table 1 ). The U.S. Office of Management and Budget's Final Information Quality Bulletin for Peer Review (Office of Management and Budget, 2004) states, "the number of reviewers may range from a few to more than a dozen." The EPA's Peer Review Handbook (EPA (United States Environmental Protection Agency), 2015) does not provide recommendations for panel size, but states, "The number of panel members selected for a peer review will depend on the issue being investigated, the time available and resources."
Addressing potential biases in peer review
In any peer review, independence of the reviewers from the work product under review is critical, and it is essential to understand and try to mitigate potential biases, defined here as subconscious prejudice that affects the objectivity of the review.
Current peer review practices may be tainted by bias and abuse, including bias introduced by the process in which reviewers are invited to participate (selection bias) or through the formulation of leading questions guiding the peer review (Barroga, 2014; Manchikanti et al., 2015; Smith, 2006) . The review bias may include any of the following: content-based bias, confirmation bias, bias due to conservatism, bias against interdisciplinary research, publication bias, and the bias of conflicts of interest (Manchikanti et al., 2015) . Reviewer bias may include the bias towards certain authors/specialties/institutions, content, confirmation of thinking, interdisciplinary research, publication bias, and the bias of conflicts of interest (Manchikanti et al., 2015) .
As a result, when faced with contradicting recommendations from reviewers, it can be difficult for the peer review manager to discern flawed comments (i.e., those subject to bias or abuse) from valid comments that better reflect the broader scientific community. Because of these limitations, the input obtained from, for instance, a journal peer review can become highly inconsistent, which may be seen as "something of a lottery" (Smith, 2006) . These limitations can be exacerbated in the context of complex, multidisciplinary manuscripts that include large data sets or require a range of expertise to cover the scientific content adequately. For these types of papers, the underlying data should be validated, but data peer review is currently not well defined (Kratz and Strasser, 2014) .
Manuscript authors are typically required to identify potential conflicts of interest by filling forms such as the International Committee of Medical Journal Editors (ICMJE) Conflict of Interest form, but this approach is less systematic for journal peer reviewers.
A potential reviewer bias could also be derived from a conflict of interest for example if the experts serve on the panels of agencies that fund their research-as exemplified by the recent discussion on how to assure independence of the reviewers recruited to EPA advisory boards (Tollefson, 2017) . Therefore, many institutions, such as The National Academies of Sciences, Engineering, and Medicine, published policies related to conflict of interest for committees used in the development of reports (http://www.nationalacademies.org/coi/index.html). Peer review processes Tiered peer review of scientific research Fig. 2 . Peer review models of industry-funded research. A. There are multiple models for peer review of industry-funded research, but not all forms of peer review carry equal weight. For example, internal reviews of scientific reports likely inspire the lowest level of confidence and should be complemented with additional review processes. Peer-reviewed scientific publications demonstrate, to some extent, the scientific rigor of the analysis shared, but a higher level of confidence can be expected from grant application reviews and reviews conducted by product safety governance councils. The most valued form of peer review will be the one conducted by blue ribbon panels recruited by regulatory agencies. B. A theoretical model of a tiered peer review of scientific research. The first level of analysis and review is conducted internally during the study conduct and reporting. The second level, Tier 1 reviews, consists of the review of study reports, data, and additional material by panels of experts. Finally, in the third level or Tier 2 review, a panel of more-senior experts reviews the outcome of individual Tier 1 reviews to extract consistent findings.
Confidence level
1.3. Scientific transparency and reproducibility -the role of peer review 1.3.1. Scientific transparency and reproducibility Since the report by Begley et al. showing that many pivotal cancer studies could not be reproduced, attention has been drawn to scientific reproducibility issues (Begley and Ellis, 2012) . In this context, peer review of scientific publications has revealed its limits, and several studies have highlighted possible reasons why much peer-reviewed scientific literature is not reproducible (Begley and Ioannidis, 2015; Couchman, 2014; Drubin, 2015; Frye et al., 2015; Gaudart et al., 2014; Iorns and Chong, 2014) . The key contributing factors include inappropriate study designs, lack of validation of reagents, inadequate documentation of methods and datasets, and insufficient sharing of data and methods with the community, all of which are essential for an experiment's analysis or replication.
Consequently, this "crisis in science" calls for a significant shift to better practices (McNutt, 2014) , as desired by scientists, funders, and regulatory agencies as well as the general public. Key points to consider to increase reproducibility of studies include (i) validation of reagents, (ii) repetition of experiments, (iii) blinding of studies whenever possible, (iv) utilization of appropriate statistics, and (v) that all results, including the ones obtained for positive and negative controls, are shared (Freedman et al., 2017) . Such a change should allow meaningful meta-analyses, hypothesis formulation, and the development of robust scientific methods.
Transparency and sharing of scientific results are expected and should be possible for all scientific studies (Boue et al., 2018) . Consequently, every scientific study should be shared, considered for its merit, and reviewed fairly and critically, independently of its origin. Interestingly, new business models are emerging, which facilitate replication of experiments by third parties as well as in-depth peer review. For example, the European Science Foundation provides a platform to support independent scientific proposal evaluation in the context of competitive funding calls.
Peer review of industry-funded research on consumer products
A peer review of industry-funded research may serve various goals, including (i) gauging which additional experiments may be needed prior to regulatory submission; (ii) providing insights on scientific plausibility to the external community of the data gathered, i.e., whether the data and conclusions are sufficiently robust to be considered in the risk assessment of materials, ingredients, and products under consideration; (iii) increasing confidence in the results of product testing, e.g., in consumer communications or scientific debates; and (iv) indirectly signaling to regulatory agencies that the manufacturer performs due diligence in providing meaningful, reliable, and unbiased data and product information. The review can be conducted in a way that is independent of the sponsor, even though the sponsor of the study also sponsors the peer review. An independent review can be organized and provided by a nonprofit organization, such as TERA, an independent nonprofit scientific body, such as the Cosmetic Ingredient Review expert panel, or a commercial service provider, such as SciPinion ® . As shown in this paper, several measures can be taken to control for some of the limitations mentioned above and to maximize the expertise in the panel, the independence of the reviewers, and the transparency of the process.
1.4. The use case: scientific assessment of a candidate modified-risk tobacco product, the Tobacco Heating System version 2.2
We retained SciPinion LLC to conduct a two-tiered scientific peer review of methods, data, and results from studies assessing THS 2.2 (Fig. 3) . The studies were part of the seven-step MRTP assessment program for THS 2.2 briefly mentioned above (Smith et al., 2016) and included aerosol chemistry, preclinical regulatory toxicology, 21 st Century Toxicology Krewski, 2009, 2010) , and clinical nicotine pharmacokinetics studies.
In the first level of peer review, the panel members conducted an indepth review of the studies to answer a set of questions relating to the choice of models, the study conduct, the transparency of the documentation, the quality of the data, and the soundness of the interpretation of results. The questionnaire also included demographic questions related to the personal background of the reviewers that could be used to identify potential conflicts of interest and sources of bias. The goal of the Tier 2 review was to build on the input received from the first peer reviewers and (1) reach overarching conclusions on Fig. 3 . Peer review structure and studies included. PK, pharmacokinetics.
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Regulatory Toxicology and Pharmacology 104 (2019) 115-127 the data package as a whole, (2) seek recommendations for improving the tiered peer review process, (3) assess the reproducibility of peer review panel results, and (4) assess potential bias in responses as a function of employment sector. The process by which the peer review was conducted and the key results obtained from the peer reviews are summarized in this article, and our response to the peer review findings, including changes in interpretation of our studies, are summarized. The findings from the peer reviews help to strengthen the scientific integrity of the studies conducted to assess the safety of THS 2.2 platform. The descriptions and results of the studies that were the topic of the peer reviews have been published elsewhere (see below) and are beyond the scope of this manuscript.
Materials and methods

Material included in the review
Our assessment framework entails seven-steps ( Fig. 1) (Smith et al., 2016) . The peer review focused on the toxicological and exposure assessment of individuals, and therefore did not include any material for steps 1 (product design and control principles), 6 (consumer perception and behavior assessment), and 7 (post-market studies and surveillance). The material that was included for the review for each of the remaining steps is the following:
-Step 2 -Aerosol chemistry and physics: chemical composition and aerosol physics analysis of the aerosol generated by the candidate MRTP (Schaller et al., 2016 ). -Step 3 -Standard toxicology assessment: (i) in vitro standard toxicity assessment (Schaller et al., 2016) , including neutral red assay, Ames assay, and mouse lymphoma assay; (ii) in vivo standard toxicology assessment: 90-day OECD Test Guide 413 study in rats (Wong et al., 2016 ). -Step 4 -Systems toxicology assessment: (i) CVD in vitro mechanistic assays: transendothelial migration assay (van der Toorn et al., 2015) and monocyte adhesion assay (Poussin et al., 2016) ; (ii) systems toxicology assessment of THS 2.2 in nasal and bronchial epithelial tissue cultures exposed to whole reference cigarette smoke or whole THS aerosol at the air-liquid interface (Iskandar et al., 2017; Zanetti et al., 2017) ; (iii) in vivo eight-month systems toxicology inhalation/cessation study in Apoe −/− mice (Lo Sasso et al., 2016; Phillips et al., 2016; Szostak et al., 2017; Titz et al., 2016) ). -Step 5: Clinical trials: two clinical pharmacokinetics studies were included: with THS 2.2 (ClinicalTrials.gov ID: NCT01959607) and THS 2.2 menthol (ClinicalTrials.gov ID: NCT01967706).
Peer review process
Input from the reviewers was elicited through participation in a "SciPi™", a request for scientists to weigh in with their opinions by answering a series of questions. The opportunity to provide an opinion in a particular SciPi™ was provided to a selection of SciPinion registrants fitting the selection criteria (see below). The SciPinion peer review process has been designed to fulfill the following requirements: broader participation of the scientific community, double-blinded review format, anonymous participation by experts, remote participation online (www.scipinion.com), consideration of panel diversity when selecting members, fair compensation for experts' time, collection of both independent and collaborative input (e.g., Delphi format), and collection, analysis, and presentation of quantitative results. This model can serve as an improved method of peer review in science, providing more balanced input to decision makers while minimizing potential bias. For more detail on the method, please refer to the publication by Kirman and colleagues (Kirman et al., 2019) .
Roles and responsibilities
The peer review process, illustrated in Fig. 4 , included the following roles:
• Sponsor: The sponsor was involved in (i) drafting the questions included in the SciPi™, (ii) preparing the data package, (iii) defining expertise criteria for panel members, and (iv) providing answers to queries from the panel members.
• Peer Review Manager: As manager of the peer review process, SciPinion's role included the following tasks: (i) coordinating all other roles (including the auditor and editor roles), (ii) finalizing questions included in the SciPi™ for the Peer Reviewers, (iii) identifying and assembling the panel of peer reviewers, (iv) implementing the SciPi™, (v) preparing and finalizing a report that summarizes the methods and results of the peer review, and (vi) optionally and at the sponsor's discretion, posting the results of the SciPi™ online.
• Independent Editor: An independent editor was retained by SciPinion to ensure that the questions in the SciPi™ (i) focused on the science issues associated with the data package, (ii) were clearly written, and (iii) were not leading or biased. The editor prepared a brief report containing the conclusions of his/her review. The identity of the editor is included in this report. Fig. 4 . Flowchart of the peer review process for this case study.
• Independent Auditor(s): One or two auditors, independent of SciPinion and of the sponsor, were hired by SciPinion to ensure that (i) peer reviewers to be recruited met the expertise requirements needed and (ii) the submitted responses can be attributed to the panel members.
• Peer Review Panel Member: Panel members were tasked with reviewing the data package, then participating in the SciPi™. To ensure that peer reviewers were free to offer their unbiased opinions, they remain anonymous to the sponsor and are not identified in the report. Their identities are only known to SciPinion and to the auditor(s).
Panel composition
The goal was to assemble five panels of five to 12 experts each for the Tier 1 primary reviews of the research and two independent panels of nine experts each for the Tier 2 review to assess the reproducibility of Tier 1 panel results, reach overarching conclusions on the data package as a whole, assess potential bias, and seek recommendations for improving the tiered peer review process.
For the purpose of this peer review, an expert is defined as an individual who meets the minimum requirements for the experience criteria provided by the sponsor and summarized in Table 2 . For more detail on each of these steps, please refer to Kirman and colleagues (Kirman et al., 2019) .
Peer review process
For the reviews reported here, a double-blinded approach was adopted. To reduce potential risks and low participation, reviewers were permitted to remain anonymous, and the sponsor's identity was not revealed beforehand. Given the content of the reports and studies, including test item specific to PMI (THS 2.2) and list of authors from PMI, we believe it is very likely that the reviewers understood PMI was the sponsor of the studies.
With respect to availability, rather than attempt to coordinate individual schedules to facilitate a face-to-face meeting, and in order to preserve anonymity, an online platform (https://app.scipinion.com) was used in which peer reviewers could participate on their own time and at their own pace. For this case study, reviews for each panel were scheduled to last four to six weeks, for an estimated workload of five to eight working days (40-60 h of work), with limited extensions (approximately one week) provided to a small number of busy reviewers.
To be fair and to encourage participation, panel members were compensated as part of their contract with SciPinion to the extent that is commensurate with the level of effort needed to provide a thorough review. Compensation was based on the estimated level of effort needed for each panel, using an hourly rate equivalent to that required for a senior-level scientist.
Each panel in the peer reviews presented here received approximately 30 questions addressing study design, methods used, results obtained, and interpretation. Question format was a mixture of multiple-choice and yes/no as well as a number of free-text formats to capture additional comments and insights from the reviewers.
For the Tier 1 review, some, but not all, of the panels included a Delphi approach (i.e., an online debate). For the second tier, the peer review consisted of three rounds for both panels, which were run independently and concurrently for the two panels:
• Round 1: peer reviewers review the data package and provide their anonymous, independent input to charge questions online.
• Round 2: online anonymous comment and debate (Delphi). Each panel member receives access to summary statistics of the answers from Round 1 from the whole panel, can read comments, and is invited to ask/answer clarifying questions of and from other panel members or the sponsor.
• Round 3: peer reviewers are given the opportunity to revise their input.
Table 2
Desired experience for each panel. Some of the requirements, including field of expertise, minimum number of years of experience in the field, number of first or last author publications, and total number of authored publications were verified for each identified expert. In order to cover all necessary expertise at the panel level, additional requirements were included at the panel level (column target panel composition).
Panel ID Review date 
. Analysis of results and consensus calculation
For the analysis of results, Likert scale responses were codified by SciPinion to a numeric score (see Fig. 5A and the publication from Kirman and colleagues for more detail (Kirman et al., 2019) ). For example:
• Answer options of "Very confident", "Confident", "Moderately confident", "Not confident at all", and "I cannot answer" corresponded to numeric scores of 2, 1, 0, −1, and not available (NA), respectively.
• Answer options of "Very convincing", "Convincing", "Moderately convincing", "Not convincing", and "I cannot answer" corresponded to numeric scores of 2, 1, 0, −1, and not available (NA), respectively.
These scores were then used to calculate summary statistics and comparative analyses (two-tailed t-test, assessment of outliers).
Panel consensus was assessed using the consensus metrics of Tastle and Wierman (2006):
where:
• p is the probability associated with the distribution under consideration
• i is an index (e.g., very confident = 2; confident = 1; somewhat confident = 0; not confident = −1)
• n is the number of answer options.
The value for the consensus metric can range from 0 (lack of consensus) to 1 (complete consensus).
Outlier analysis
An assessment was also conducted to evaluate the degree to which individual panel members' response patterns differed from the overall pattern for the group. The codified Likert-scale responses results from all panel members were compared to assess whether any member(s) consistently stood apart from the group (Fig. 5B ). Responses were stratified into three bins as follows:
• The expert is less confident than the other experts (response < mean −0.5 score units).
• The expert's confidence is similar to that of other experts (response within mean ± 0.5 score units).
• The expert is more confident than the other experts (response > mean + 0.5 score units).
As a result, potential outliers were flagged for more in depth analysis of a likely bias, based on the review of the demographics questions -but not necessarily discarded -if one of the following conditions was observed:
• An expert's frequency of responses in bin 2 was unusually low (i.e., fewer than 30% of responses fell within 0.5 score units of the mean response score for other members).
• An expert's frequency of responses in bins 1 or 3 was unusually low (i.e., fewer than 5% of responses were less than or greater than 0.5 score units below or above the mean for other members).
Access to relevant information
To ease access to relevant information and data for panel members, information was made available on a now retired web platform (https://systox.sbvimprover.com/). Owing to the usefulness of such a platform, the INTERVALS™ platform has been redesigned and is now accessible at https://www.intervals.science for anyone to access details of study design, results, and data files for studies relevant to tobacco harm reduction and mechanisms related to tobacco-relevant diseases (Boue et al., 2017) . Data packages that summarized the studies and the obtained results were prepared by the sponsor and included links to peer reviewed scientific publications. This permitted the presentation of large quantities of data and information in the most user-friendly way possible while maintaining scientific accuracy:
• Each study under review had a dedicated page summarizing the study design, methods used, and relevant results and providing access to the data.
• For each question addressed to panel members, relevant background information and links to results and methods were given on dedicated question pages.
• Some tools for data visualization and analysis were made available to ease data review. Those were explained, and tutorials and videos were provided on the tools page of the platform.
Results and discussion
Studies that were under review by the panels have been published on INTERVALS (https://intervals.science) alongside the results obtained in this peer review. Results from the Tier I panel reviews, including comments are available at https://www.intervals.science/ studies/#/tieri_peer_review_ths22 and results from the Tier II reviews, including comments and debate threads are available at https://www. intervals.science/studies/#/tierii_peer_review_ths22.
Alternatively, all results can be accessed online on the Scipinion online platform: With respect to relevant experience, we defined minimum expertise criteria (Table 2) , and candidates were ranked by SciPinion and the auditors by multiple objective metrics of their experience (see section "Peer review process"). On average, the expertise of the peer reviewers compared well with that of reviewers typically involved in U.S. Food and Drug Administration (FDA) advisory committees (Table 3) .
For the Tier 2 peer review, the panel composition reflected some general principles of regulatory review panels, including the recruitment of physicians, dentists, scientists, or health care professionals practicing in the areas of oncology, pulmonology, cardiology, toxicology, pharmacology, addiction, or any other relevant specialty. The sole additional criterion was that the panels comprised nine members from the following sectors: three former (retired) government scientists/experts, three scientists/experts from academic/research institutions, and three scientists/experts from industry. It must be noted that one member of Panel 2B did not complete the review, so the final number of reviewers in that panel was eight.
Assessment of potential bias and reproducibility
For the review reported here, several measures served to minimize the introduction of process bias:
• Draft charge questions were prepared by the study sponsor and reviewed by SciPinion and by an independent, third-party editor to ensure that the wording was neither leading nor biased.
• Open-ended questions (free-text format, "Please feel free to expand/clarify …") were included to ensure that any expansions/clarifications from the reviewer were captured adequately.
• Questions were explicitly included in the SciPi™ to assess participant demographics (e.g., smoking status, previous employment with the sponsor or competitors, age, sector of employment). These questions were not used as exclusion criteria, but rather to understand how these factors (i.e., potential sources of bias) correlated with the responses received.
With respect to reviewer abuse, it was assumed that this was relatively rare and that by including a sufficiently large number of reviewers, any outlier response patterns by an individual reviewer would become readily apparent or could be tested (e.g., by multivariate outlier analysis).
Some reviewers (especially in the Tier 2 reviews) reported working for or having received funding from a regulatory agency, including those with regulatory jurisdiction over tobacco, in the past. A few reviewers reported working for another tobacco company in the past or receiving funding from a tobacco company in the past. All reviewers, however, stated that they believed they could remain impartial with respect to this peer review. Outlier analyses confirmed that there was no significant negative or positive bias from any of the reviewers, with the exception of one reviewer in Panel 1A, who was excluded from the analysis.
To further investigate the influence of panel composition on the reproducibility of the review outcomes, various stratifications were assessed. One peer reviewer from Tier 2 (#1342) remarked:
Although a few slight deviations are noted where specific strata are under-represented (e.g., n = 1 for consulting in Fig. 4B ; n = 1 for 25-35 years in Fig. 4C ), these results indicate remarkable consistency in the results across various strata. For example, results from USA experts (71% supportive) are indistinguishable from Japanese experts (75% supportive), results from academic experts (81% supportive) are indistinguishable from pharmaceutical industry experts (82% supportive), less experience experts are indistinguishable from more experienced experts when stratified by either number of years since PhD (5-15 years = 77% supportive vs. 15-25 years = 76% supportive) or by publication record (76-81% supportive for the three strata considered). The overall consistency of the results by various stratification suggests that the results of peer review by this panel would be highly reproducible (i.e., similar results are expected if the review process were to be repeated using a different panel).
Blinding: anonymity of panel members
For the reviews reported here, a double-blinded approach was adopted. This approach was accepted by the majority of participants. With respect to withholding peer reviewers' identities, the reviewers were asked, "How important is your anonymity to your participation in this peer review?" Fig. 6 displays the responses. Reviewer anonymity was somewhat or very important to the participation of more than 90% of the reviewers, with no difference between the two tiers. It is fair to say that without the guarantee of anonymity, the pool of candidate reviewers would be much smaller and likely to lower the level of expertise among panel members and possibly the quality of the review.
Although some journals, including F1000Research, are conducting open (or unblinded) reviews, the process typically includes sending the submitted manuscript to one to three reviewers (Cho and Park, 2013) who are not known to the study authors (single-blinded), and in rare cases, the author names are not included with the manuscript (doubleblinded). In contrast, peer reviews for many regulatory policies and assessments are usually conducted using an unblinded design. For example, in the EPA's Peer Review Handbook (EPA (United States Environmental Protection Agency), 2015), this issue is made explicit: "Can the Identity of Peer Reviewers Be Kept Anonymous by EPA? No, the identity of peer reviewers cannot be kept anonymous by EPA." The primary benefit of using an unblinded format is that it ensures transparency, which in turn discourages misuse and abuse of the peer reviewer. There are, however, some benefits to blinding. By withholding the review sponsor's identity, any potential bias toward the sponsor from a reviewer may be avoided. It should be noted, however, that the identity of the authors of the studies under review is easy to guess, if not made explicit, and may also be a source of bias. In addition, there are benefits to withholding peer reviewers' identities. Scientists, by their very nature, may not be willing participants in controversy and conflict and may withdraw from the debate if their identity is revealed. This is consequential, because often the most critical decisions, such as those designated as influential scientific information or highly influential scientific information requiring peer review (Office of Management and Budget, 2004) , are also the most controversial. Additionally, participation in panels on controversial topics may make scientists the targets of public and private attacks by advocacy groups (Batra, 2015; Rost, 2015) .
Opportunity for information exchange between the panel members
Peer reviewers may provide opinions either independently or collaboratively. Although there are benefits to having reviewers work collaboratively (e.g., develop consensus positions), there are a number of potential pitfalls that can adversely affect the input received from a collaborative review. These pitfalls have been reviewed (Sunstein and Hastie, 2014) and are discussed in more details by Kirman and colleagues (Kirman et al., 2019) . The Delphi method allows for anonymous multi-round input from peer reviewers (Hsu and Sandford, 2007) in what Sunstein and Hastie term a "statistical group" rather than a "deliberating group" (Sunstein and Hastie, 2014) . When asked, a majority of Tier 2 panel members said that the interaction with other panel members during the online debate phase was useful or very useful (Fig.7) . The online debate permitted members to (i) understand the rationale of other panel members for particular answers, (ii) obtain an expert opinion on topics on which panel members were not dedicated experts, (iii) formulate answers to questions from the sponsor, and (iv) offer the sponsor a rationale for particular answers (although most questions included a comment field, answers were not always justified in-depth).
Compensation
To estimate the importance of compensation in each panel, a question was asked of the peer reviewers: "For future participation, how important is compensation for your participation?" The majority of reviewers would prefer some level of compensation and found the level of compensation offered for participation in the panels appropriate. Only one of 65 reviewers replied that he/she would be willing to participate without compensation (Fig. 8) . This finding corroborates the difference between reviews conducted for journals and more complex reviews of research results, intended for purposes such as risk assessment. Peer reviewers for journals are generally not compensated. Some journals provide nonmonetary incentives (e.g., electronic access to their holdings for a limited period, continuing education credits, acknowledgments, appointments to review boards) (Gasparyan et al., 2013) . In most cases, however, journal peer review is considered an obligatory, voluntary service performed without compensation for the benefit of the scientific community. For regulatory decision peer reviews, some compensation, such as travel expenses and honoraria, may be provided. Pay in the range of $50-100 per hour plus travel expenses is most common, at least for EPA peer reviewers and special government employees. In a survey of 551 reviewers, 54% indicated that financial incentives encourage reviewers to accept requests for review (Tite and Schroter, 2007) , but 60% indicated that small financial incentives alone would not be sufficient to encourage acceptance. In short, scientists are likely to participate in peer review, but only if they are fairly compensated for their time.
Tiered peer review process
The Tier 2 panels were tasked with evaluating the peer review process and summarizing findings from the five Tier 1 panels. To assess confidence in the tiered peer review process, the following question was asked of members of the Tier 2 panels: "Concerning the Tier 1 review process, please provide the appropriate descriptor for your confidence in the areas listed below: (i) The selection of areas of expertise was appropriate to review the studies; (ii) the assessment of reviewers' qualification was adequate; (iii) the necessary level of expertise was met in the panels; (iv) the reviewers had sufficient access to information on the studies; (v) the questions were expressed in a way that allowed for an unbiased assessment of the studies; (vi) panel members had the opportunity to freely express their scientific opinion; (vii) the anonymity of the reviewers does not create distrust in the outcome of the review; and (viii) the two-stage SciPi™ evaluation process (individual plus Delphi) is appropriate for a scientifically sound review." The confidence scale provided comprised the options "very confident"/ "confident"/"moderately confident"/"not at all confident"/"I cannot answer". Fig. 9 illustrates the responses obtained. Overall, both panels were mostly confident or very confident about each aspect of the process.
A more detailed evaluation of the Tier 2 panels' peer review results concerning the review process is provided in Supplementary Fig. 1. 
Peer review results concerning the studies conducted
Evaluation of study designs and methodology
The panels were tasked with assessing whether the study design, choice of models, and the methods used were appropriate for addressing the comparative assessment of a candidate MRTP, THS 2.2, and a reference cigarette. As summarized in Fig. 9 under "Studies" and Regulatory Toxicology and Pharmacology 104 (2019) 115-127 presented in detail in Supplementary Fig. 2 , all Tier 2 reviewers found the positive rating of the choice of models and study designs by the Tier 1 panels convincing or moderately convincing (Supplementary Fig. 2A ), and all were confident or very confident that state-of-the-art methods had been used ( Supplementary Fig. 2B ). Regarding the added value of the systems toxicology approaches, the bandwidth of the Tier 2 responses was broader ( Supplementary Fig. 2C ) and ranged on Panel 2A from "not at all confident" to "very confident" (one reviewer each), while the majority of reviewers on both panels selected "confident" or "moderately confident." The reviewers also took the opportunity to add free-text comments addressing the most critical comments and identified gaps from the Tier 1 review. Extended study duration and multiple doses (including a carcinogenesis study), alternative exposure modes, and comparative studies using additional mouse strains and human cell lines were among the most frequent recommendations. In addition, a couple of additional in vitro and in vivo endpoints and biomarkers were suggested as well as a causal validation of critical results from "omics" platforms. Many of these aspects have been addressed in the meantime by a number of studies that were not yet completed and available when the SciPi™ review was conducted (e.g., an A/J mouse 18-month carcinogenicity study). Some of the methodological suggestions, however, appeared to be driven mainly by academic goals, as was critically mentioned by one of the Tier 2 reviewers:
The reviewers offered numerous scientifically sound suggestions for further work. In my opinion, about half of these reflected what I would call an academic point of view. That is, they described refinement of systems toward better delineation of mechanisms of action, classic investigation of "responsible" components of mixtures, effects of metabolism and so on. I assumed that the sponsor may have a more practical or focused interest in demonstrating the hypothesized benefits of alternatives to cigarette smoking.
Over this purely scientific interest, the aim of the sponsor's research, i.e., to provide robust evidence that demonstrates the product's potential for reduced risk, needs to remain the focus regarding costs and efforts while keeping the numbers of animals to the absolutely necessary level.
Evaluation of the quality, annotation, and presentation of data
Tier 2 panel members were also asked to evaluate the Tier 1 ratings of the quality and depth of data, including data annotation, sharing, and presentation of results. As summarized in Fig. 9 under "Data & results" and presented in detail in Supplementary Fig. 3 , most Tier 2 reviewers were "confident" or "very confident" about the positive ratings by Tier 1 panels. One histopathology reviewer from Tier 1 commented that the magnification of the digital histological images provided for checking the histopathology scores was insufficient for certain endpoints. Although the other histopathology experts did not demand for higher resolution, a possibility for the sponsor to provide -on-demand -very high-resolution digital images could be implemented. A general provision of all histological images at the highest possible resolution was considered impracticable due to the large file sizes and the high number of samples provided.
Evaluation of the interpretation of the data and results and of the conclusions drawn by study authors
The majority of Tier 1 panel members found the interpretation of the results by the study authors reasonable, and most of the Tier 2 reviewers were "confident" or "very confident" in that outcome ( Fig. 9 ; details in Supplementary Fig. 4 ). Concerning gaps in the results interpretation and discussion, the panels did not identify many significant issues; there was, for example, a suggestion that "omics" data, particularly from proteomics, should be interpreted more deeply in terms of toxicity mechanisms and disease biomarkers/endpoints. As noted by reviewer 1407, many of the Tier 1 panel members provided responses pointing to the need for additional studies/data rather than new interpretation and discussion of existing results (see "Evaluation of study designs and methodology"). Another Tier 2 reviewer (1354) supposed that the somewhat lower confidence in the value of "omics" data on Tier 1 Panel 1A could be a consequence of the composition of this panel, which was largely populated by experts in veterinary pathology, "a discipline that is not yet experienced with such data". This may be balanced by including the evaluation in multiple panels with different expertise distributions.
3.2.4. Evaluation of the evidence that THS 2.2 is likely to have reduced risk potential compared with conventional cigarettes Two charge questions addressed the usefulness of the reviewed research results for a risk assessment/FDA-MRTP application approach: (i) "Based on the responses of the panel members, how convincing is the evidence that switching and cessation were causing comparable changes in the experimental models/the study cohort?" and (ii) "Based on the evaluation by the panel members, how convincing is the evidence that THS 2.2 is likely to have the potential for reduced risk compared with conventional cigarettes?" Fig. 9 and Supplementary  Fig. 5A show that the evidence that switching to THS 2.2 has a comparable effect to switching to fresh air (cessation) was rated "convincing" or "very convincing" by 11 of the 17 Tier 2 reviewers (65%), and only one reviewer selected "not convincing". The more general question concerning the demonstration of the potential for reduced risk of THS 2.2 use was evaluated more critically. Nine of the 17 reviewers (53%) voted "convincing" or "very convincing," and two reviewers found the evidence "not convincing." This outcome can be explained, at least in part, by the fact that only a subset of studies conducted for the risk assessment was available for peer review at the time. The data package was however already substantial enough to warrant this in-depth peer review and it was beneficial for the sponsor to receive feedback from the panels of experts before the whole assessment was completed.
Conclusions
Independent peer reviews are central elements in the evaluation and validation of scientific results. This is true for reviews of manuscripts submitted for publication in scientific journals and for decision making by regulatory agencies during the registration process of new drugs, consumer products, pesticides, and chemicals. Similarly, manufacturers may wish to obtain an independent peer review on the quality of research results at a level that exceeds a journal review as part of a risk assessment or another decision-making process.
This review has been conducted as a scientific study, (i) with a relatively high number of reviewers per panel who were given appropriate time for their review, which allowed on the one hand to obtain detailed answers with their associated rationale and on the other hand to detect potential outliers, (ii) with a second tier panel who assessed the validity of this peer review approach, and (iii) with two parallel panels of similar composition on the second tier who went independently through the whole process, enabling us to evaluate the variability of the outcome of such an assessment. It is in fact remarkable how congruent the overall conclusions were in the two panels. Overall, the results obtained in the peer review described here are supportive of the study design, results, and interpretation of the studies assessing the potential MRTP THS 2.2. They have enabled us to confirm the plausibility of the evidence we had gathered and to appropriately complement our evidence package in view of regulatory submissions.
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